Treatment for metastatic castration-sensitive prostate cancer and a tumor or inherited mutation in BRCA1, BRCA2, ATM, BRIP1, CHEK2, PALB2 or related gene
Clinicaltrials.gov identifier:NCT04497844
Study Contact Information:
For additional information, please contact:
Janssen study contact at:
844-434-4210 or via email at: Participate-In-This-Study@its.jnj.com
Treatment for Metastatic Castration-Sensitive Prostate Cancer and Inherited or Tumor Mutations in DNA Damage Repair Genes (Amplitude)
Treatment for metastatic castration-sensitive prostate cancer and a tumor or inherited mutation in BRCA1, BRCA2, ATM, BRIP1, CHEK2, PALB2 or related gene
Clinicaltrials.gov identifier:NCT04497844
Study Contact Information:
For additional information, please contact:
Janssen study contact at:
844-434-4210 or via email at: Participate-In-This-Study@its.jnj.com
About the Study
The goal of AMPLITUDE is to see if adding the niraparib to standard of care hormone therapy ( Acetate, prednisone and (ADT) is safe and more effective than standard of care alone. The study is enrolling people who have castration-sensitive cancer and have an inherited or tumor mutation in one of the following genes involved in damage repair: , , , , FANCA, , RAD51B and RAD54L. NOTE: This study is no longer enrolling patients.
This Study is Open To:
NOTE: This study is no longer enrolling patients.
This Study is NOT Open To:
NOTE: This study is no longer enrolling patients.
Study Contact Information:
For additional information, please contact:
Janssen study contact at:
844-434-4210 or via email at: Participate-In-This-Study@its.jnj.com